The T1D Fund Appoints Industry Veteran Elizabeth Mily as CEO to Accelerate Development of Type 1 Diabetes Cures Through Impact Investing

Rhea-AI Summary

The T1D Fund, an impact investment fund focused on type 1 diabetes solutions, has appointed Elizabeth Mily as CEO. Mily brings over 30 years of experience from roles at Bristol Myers Squibb, Goldman Sachs, and Barclays, where she specialized in corporate strategy and business development.

In her new role, Mily will guide the fund's resource deployment and expand strategic partnerships to build an ecosystem for new therapies. She will serve as the fund's lead public ambassador, working to increase awareness and investment in T1D research and innovation.

Prior to joining T1D Fund, Mily served as Executive Vice President of Strategy & Business Development at Bristol Myers Squibb, overseeing company strategy, external innovation, and business development. She currently serves on the Board of Solventum (NYSE: SOLV) and Ampersand Biomedicines.

Positive

• Appointment of seasoned executive with 30+ years of pharma and healthcare investment experience
• Strong strategic partnerships background with major biopharma companies
• Extensive experience in managing business development and external innovation
• Current board member of NYSE-listed Solventum (SOLV)

Negative

• None.

News Market Reaction

-0.65%

1 alert

-0.65% News Effect

On the day this news was published, SOLV declined 0.65%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Former Bristol Myers Squibb, Goldman Sachs, and Barclays executive brings deep expertise in corporate strategy, partnership development, public and private financial markets, and management as the organization evolves its leadership and investment strategy

Appointment signals plans to capitalize on previous success and maximize impact by expanding equity investments and partnerships with venture capital, large biopharma, and key foundations with a proven team leader and dealmaker

BOSTON, Jan. 8, 2025 /PRNewswire/ -- The T1D Fund, an impact investment fund with a focus on accelerating life-changing solutions to treat, prevent, and cure type 1 diabetes (T1D), today announced it appointed Elizabeth Mily as Chief Executive Officer. With more than 30 years of pharma, healthcare investment banking, and strategic leadership experience, Mily will leverage her mission-driven commitment to spearheading the next chapter of the Fund, guiding continued deployment of resources and supporting a comprehensive approach to curing type 1 diabetes. Under her leadership, the T1D Fund expects to build on its current momentum, growing its investment team and expanding strategic partnerships with an eye toward building an ecosystem for delivering new therapies. As the T1D Fund's lead public ambassador, Mily will work to elevate awareness of and investment in leading research, innovation, and the need for cures for type 1 diabetes.

"Elizabeth brings a bold strategic vision to the T1D Fund during an exciting period of our evolution. She is the ideal choice to lead the next chapter as we identify and invest in cutting-edge approaches for treating type 1 diabetes," said Tim Clark, Chair of the Board of Directors at the T1D Fund.

Mily joins the T1D Fund after most recently serving as Executive Vice President, Strategy & Business Development, at Bristol Myers Squibb, where she oversaw the company strategy and approach to sourcing external innovation, including all business development activities, strategic partnerships, alliance management, mergers and acquisitions, and the company's broad equity investing portfolio. Previously, she held senior roles at Barclays, Thermo Fisher Scientific, and Goldman, Sachs & Co., where she led strategy and transactions for the healthcare, life sciences, and biopharma sectors. Mily currently serves on the Board of Solventum Corporation (NYSE: SOLV), where she sits on the Audit and Quality, Science & Technology Committees; she also serves on the Board of Ampersand Biomedicines, a private Flagship Pioneering portfolio company.

"The T1D Fund's unique position as an impact investor enables it to go beyond capital deployment to proactively work with biopharma to bring forward innovative therapies with the potential to translate to transformative cures," said Mily. "As someone who knows first-hand the serious impacts the disease has on individuals and their loved ones, I am eager to build upon the team's meaningful work and partnerships to propel treatments that can improve the lives of those with type 1 diabetes."

"Elizabeth's wealth of industry knowledge will be instrumental in the T1D Fund's ability to serve as a true biopharma partner—capitalizing on unique opportunities and directing market attention to develop treatments for patients with type 1 diabetes," said David Panzirer, Trustee of The Leona M. and Harry B. Helmsley Charitable Trust. "Leveraging its deep relationships with Helmsley Charitable Trust and Breakthrough T1D alongside Mily, the Fund is well-positioned to successfully drive a multitude of breakthroughs to market readiness."

About the T1D Fund: A Breakthrough T1D Venture, LLC
The T1D Fund is an impact investment fund accelerating life-changing solutions to treat, prevent, and ultimately cure type 1 diabetes (T1D). Launched in December 2016, it is the first scaled, mission-driven venture impact fund established to catalyze the development of T1D cure-oriented therapies through equity investments in partnership with additional sources of capital, including venture capital, corporations, and foundations. T1D Fund is managed by a dedicated team of investment professionals that invest in innovative approaches and novel mechanisms with curative potential in type 1 diabetes. Its focus is strategically aligned with Breakthrough T1D (formerly JDRF) and the Helmsley Charitable Trust, the leading global organizations funding T1D research and working to change the lives of those who are affected by T1D. Learn more at t1dfund.org. Follow the T1D Fund on Linkedin.

Media Contact
Lia Dangelico
lia.dangelico@deerfieldgroup.com
540-303-0180 

View original content to download multimedia:https://www.prnewswire.com/news-releases/the-t1d-fund-appoints-industry-veteran-elizabeth-mily-as-ceo-to-accelerate-development-of-type-1-diabetes-cures-through-impact-investing-302345016.html

SOURCE The T1D Fund

FAQ

What is Elizabeth Mily's background before joining T1D Fund as CEO?

Elizabeth Mily previously served as Executive Vice President of Strategy & Business Development at Bristol Myers Squibb, and held senior roles at Barclays, Thermo Fisher Scientific, and Goldman Sachs, with over 30 years of experience in pharma and healthcare investment banking.

What are Elizabeth Mily's responsibilities as T1D Fund's new CEO?

As CEO, Mily will guide resource deployment, expand strategic partnerships, build an ecosystem for new therapies, and serve as the fund's lead public ambassador to increase awareness and investment in T1D research and innovation.

What boards does Elizabeth Mily currently serve on, including SOLV?

Elizabeth Mily serves on the Board of Solventum (NYSE: SOLV), where she sits on the Audit and Quality, Science & Technology Committees, and on the Board of Ampersand Biomedicines, a private Flagship Pioneering portfolio company.

What is the T1D Fund's primary investment focus?

The T1D Fund is an impact investment fund focused on accelerating life-changing solutions to treat, prevent, and cure type 1 diabetes (T1D) through strategic investments and partnerships.